Attenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis

OncoImmunology

Volumn 3, Issue 5, 2014, Pages

  Lizotte, Patrick H ^a   Baird, Jason R ^a   Stevens, Cynthia A ^a   Lauer, Peter ^c   Green, William R ^a,b   Brockstedt, Dirk G ^c   Fiering, Steven N ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NORRIS COTTON CANCER CENTER   (United States)

^c Aduro BioTech Inc   (United States)

Author keywords

Immunosuppression; Immunotherapy; Listeria; Ovarian cancer; Tumor associated macrophages

Indexed keywords

B7 ANTIGEN; BACTERIAL VACCINE; CD86 ANTIGEN; CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; LISTERIA VACCINE; NITRIC OXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CYTOLYSIS; DOWN REGULATION; GENETIC TRANSCRIPTION; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOSTIMULATION; LISTERIA MONOCYTOGENES; MICROBIAL ATTENUATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEAR REPROGRAMMING; OVARY CANCER; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; REPOLARIZATION; SUPPRESSOR CELL; SURVIVAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; UPREGULATION;

EID: 84904061702     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28926     Document Type: Article

References (31)

1. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354:34-43; PMID:16394300; http://dx.doi.org/10.1056/NEJMoa052985
2. Aghajanian C, Blank SV, GoffBA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebocontrolled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30:2039-45; PMID:22529265; http://dx.doi.org/10.1200/JCO.2012.42.0505
3. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a metaanalysis. JAMA 2011; 305:487-94; PMID:21285426; http://dx.doi.org/10.1001/jama.2011.51
4. Lavoué V, Thédrez A, Levêque J, Foucher F, Henno S, Jauffret V, Belaud-Rotureau MA, Catros V, Cabillic F. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med 2013; 11:147; PMID:23763830; http://dx.doi.org/10.1186/1479-5876-11-147
5. Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, Preisser L, Anegon I, Catala L, Ifrah N, et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007; 110:4319-30; PMID:17848619; http://dx.doi.org/10.1182/blood-2007-02-072587
6. Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P. Interferon-γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int J Cancer 2009; 125:367-73; PMID:19378341; http://dx.doi.org/10.1002/ijc.24401
7. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G, Zou W. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007; 67:8900-5; PMID:17875732; http://dx.doi.org/10.1158/0008-5472.CAN-07-1866
8. Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, Krause M, Schwörer AM, Wagner U, Müller-Brüsselbach S, et al. Mixedpolarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer 2014; 134:32-42; PMID:23784932
9. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008; 205:1261-8; PMID:18490490; http://dx.doi.org/10.1084/jem.20080108
10. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23:549-55; PMID:12401408; http://dx.doi.org/10.1016/S1471-4906(02)02302-5
11. Zhao Q, Kuang DM, Wu Y, Xiao X, Li XF, Li TJ, Zheng L. Activated CD69+ T cells foster immune privilege by regulating IDO expression in tumorassociated macrophages. J Immunol 2012; 188:1117-24; PMID:22184722; http://dx.doi.org/10.4049/jimmunol.1100164
12. Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 2012; 18:858-68; PMID:22147941; http://dx.doi.org/10.1158/1078-0432.CCR-11-2121
13. Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009; 27:3975-83; PMID:19389451; http://dx.doi.org/10.1016/j.vaccine.2009.04.041
14. Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW Jr. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A 2004; 101:13832-7; PMID:15365184; http://dx.doi.org/10.1073/pnas.0406035101
15. Bahjat KS, Liu W, Lemmens EE, Schoenberger SP, Portnoy DA, Dubensky TW Jr., Brockstedt DG. Cytosolic entry controls CD8+-T-cell potency during bacterial infection. Infect Immun 2006; 74:6387-97; PMID:16954391; http://dx.doi.org/10.1128/IAI.01088-06
16. Kim SH, Castro F, Paterson Y, Gravekamp C. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res 2009; 69:5860-6; PMID:19584282; http://dx.doi.org/10.1158/0008-5472.CAN-08-4855
17. Seavey MM, Maciag PC, Al-Rawi N, Sewell D, Paterson Y. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model. J Immunol 2009; 182:5537-46; PMID:19380802; http://dx.doi.org/10.4049/jimmunol.0803742
18. Bahjat KS, Prell RA, Allen HE, Liu W, Lemmens EE, Leong ML, Portnoy DA, Dubensky TW Jr., Brockstedt DG, Giedlin MA. Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease. J Immunol 2007; 179:7376-84; PMID:18025181; http://dx.doi.org/10.4049/jimmunol.179.11.7376
19. Yoshimura K, Laird LS, Chia CY, Meckel KF, Slansky JE, Thompson JM, Jain A, Pardoll DM, Schulick RD. Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T cells. Cancer Res 2007; 67:10058-66; PMID:17942940; http://dx.doi.org/10.1158/0008-5472.CAN-07-0573
20. Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A, Buckanovich RJ, Holtz DO, Jenkins A, Na H, Zhang L, et al. Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004; 10:950-8; PMID:15334073; http://dx.doi.org/10.1038/nm1097
21. Baird JR, Fox BA, Sanders KL, Lizotte PH, Cubillos-Ruiz JR, Scarlett UK, Rutkowski MR, Conejo-Garcia JR, Fiering S, Bzik DJ. Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment. Cancer Res 2013; 73:3842-51; PMID:23704211; http://dx.doi.org/10.1158/0008-5472.CAN-12-1974
22. Spear P, Barber A, Rynda-Apple A, Sentman CL. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF. J Immunol 2012; 188:6389-98; PMID:22586039; http://dx.doi.org/10.4049/jimmunol.1103019
23. Singh-Jasuja H, Thiolat A, Ribon M, Boissier MC, Bessis N, Rammensee HG, Decker P. The mouse dendritic cell marker CD11c is down-regulated upon cell activation through Toll-like receptor triggering. Immunobiology 2013; 218:28-39; PMID:22445076; http://dx.doi.org/10.1016/j.imbio.2012.01.021
24. Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, Lu LF, Gondek D, Wang Y, Fava RA, et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 2011; 208:577-92; PMID:21383057; http://dx.doi.org/10.1084/jem.20100619
25. Hart KM, Bak SP, Alonso A, Berwin B. Phenotypic and functional delineation of murine CX(3)CR1 monocyte-derived cells in ovarian cancer. Neoplasia 2009; 11:564-73, 1, 573; PMID:19484145
26. Serbina NV, Salazar-Mather TP, Biron CA, Kuziel WA, Pamer EG. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 2003; 19:59-70; PMID:12871639; http://dx.doi.org/10.1016/S1074-7613(03)00171-7
27. Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ. Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 2010; 10:453-60; PMID:20467425; http://dx.doi.org/10.1038/nri2784
28. Ezekowitz RA, Gordon S. Down-regulation of mannosyl receptor-mediated endocytosis and antigen F4/80 in bacillus Calmette-Guérin-activated mouse macrophages. Role of T lymphocytes and lymphokines. J Exp Med 1982; 155:1623-37; PMID:6978922; http://dx.doi.org/10.1084/jem.155.6.1623
29. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011; 331:1612-6; PMID:21436454; http://dx.doi.org/10.1126/science.1198443
30. Kernbauer E, Maier V, Stoiber D, Strobl B, Schneckenleithner C, Sexl V, Reichart U, Reizis B, Kalinke U, Jamieson A, et al. Conditional Stat1 ablation reveals the importance of interferon signaling for immunity to Listeria monocytogenes infection. PLoS Pathog 2012; 8:e1002763; PMID:22719255; http://dx.doi.org/10.1371/journal.ppat.1002763
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Δ Δ C(T)) Method. Methods 2001; 25:402-8; PMID:11846609; http://dx.doi.org/10.1006/meth.2001.1262